enGene Therapeutics (ENGN) Company Profile

Complete business overview, executive team, trading details, and corporate information.

enGene Therapeutics Inc.

ENGN•Nasdaq Stock Market•Healthcare•Biotechnology

About enGene Therapeutics

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)

CurrencyUSD - USD

TypeStock

Share ClassClass A Shares

Contact Information

Websitewww.engene.com

Phone514 332 4888

Address

4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada

Corporate Identifiers

CIK0001980845

CUSIP29286X101

ISINCA29286X1015

SIC2836

Leadership Team & Key Executives

Ronald H. W. Cooper

President, Chief Executive Officer and Director

David Ryan Daws

Chief Financial Officer and Head of Business Development

Dr. Anthony T. Cheung Ph.D.

Co-Founder and Chief Scientific Officer

Dr. Alexander Nichols Ph.D.

Chief Strategy and Operations Officer

Joan Connolly

Chief Technology Officer

Lee G. Giguere

Chief Legal Officer and Corporate Secretary

Tara Place M.B.A.

Senior Vice President of Human Resources

Matthew Boyd

Chief Regulatory Officer

Jill Buck

Chief Development Officer

Amy Pott

Chief Global Commercialization Officer

About enGene Therapeutics

Company Information

Stock Details

Contact Information

Corporate Identifiers

Leadership Team & Key Executives